Background: Artificial intelligence (AI), including machine learning (ML) and deep learning, has the potential to revolutionize biomedical research. Defined as the ability to "mimic" human intelligence by machines executing trained algorithms, AI methods are deployed for biomarker discovery.
Objective: We detail the advancements and challenges in the use of AI for biomarker discovery in ovarian and pancreatic cancer.